Updated 2026 Japanese Diagnostic Criteria for Takayasu Arteritis
Abstract
Takayasu arteritis (TAK) is a chronic, refractory large-vessel vasculitis designated as a Designated Intractable Disease in Japan. The Japanese diagnostic criteria for TAK, last revised in 2017, have been updated to the 2026 version as part of the Japanese Circulation Society 2026 guidelines on the management of large vessel vasculitis, and are presented here in English for the first time. The revision was conducted through a 3-round modified Delphi process involving a panel of 21 experts, supplemented by email discussion and an in-person meeting. The updated criteria incorporate 3 major changes: new symptoms were added and a qualifying statement introduced in Section A; pulmonary artery involvement was elevated to a main criterion in Section B; and IgG4-related periaortitis, Cogan syndrome, and drug-induced aortitis were added in Section C. These updates reflect advances in imaging technology and international classification frameworks, with an emphasis on improving diagnostic sensitivity to reduce missed diagnoses.
Related
- Clinical Implications of the Age Threshold in the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Real-World Study of Patients Aged over 61 Years
- P051 Diagnostic Challenge of Takayasu arteritis in a patient with inflammatory bowel disease
- P062 Treat inflammation or accept the damage? - “a diagnostic dilemma in advanced Takayasu arteritis”
- Recanalization of a diagonal coronary branch in Takayasu arteritis
- Bilateral Pulmonary Arterial Involvement in Takayasu Arteritis
BibTeX
@article{yoshifuji2026updated,
title = {{Updated 2026 Japanese Diagnostic Criteria for Takayasu Arteritis}},
author = {Hajime Yoshifuji and Haruhito A. Uchida and Yasuhiro Onishi and Yoshia Miyawaki and Eisuke Amiya and Ryotaro Asano and Takuya Hashimoto and Tomonori Ishii and Jun Ishizaki and Shuichi Ito and Toru Iwahashi and Naomi Iwata and Takatoyo Kiko and Yasuhiro Maejima and Takako Miyamae and Hiroko Nagafuchi and Kunihiro Shigematsu and Tsuyoshi Shirai and Natsuka Umezawa and Takahiko Sugihara and Yoshiko Watanabe and Naoto Tamura and Yoshikazu Nakaoka},
journal = {Circulation Journal},
year = {2026},
month = aug,
doi = {10.1253/circj.cj-26-0679},
url = {https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0679/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Updated 2026 Japanese Diagnostic Criteria for Takayasu Arteritis
AU - Hajime Yoshifuji
AU - Haruhito A. Uchida
AU - Yasuhiro Onishi
AU - Yoshia Miyawaki
AU - Eisuke Amiya
AU - Ryotaro Asano
AU - Takuya Hashimoto
AU - Tomonori Ishii
AU - Jun Ishizaki
AU - Shuichi Ito
AU - Toru Iwahashi
AU - Naomi Iwata
AU - Takatoyo Kiko
AU - Yasuhiro Maejima
AU - Takako Miyamae
AU - Hiroko Nagafuchi
AU - Kunihiro Shigematsu
AU - Tsuyoshi Shirai
AU - Natsuka Umezawa
AU - Takahiko Sugihara
AU - Yoshiko Watanabe
AU - Naoto Tamura
AU - Yoshikazu Nakaoka
PY - 2026
DA - 2026/08/27
JO - Circulation Journal
DO - 10.1253/circj.cj-26-0679
UR - https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0679/_article
AB - Takayasu arteritis (TAK) is a chronic, refractory large-vessel vasculitis designated as a Designated Intractable Disease in Japan. The Japanese diagnostic criteria for TAK, last revised in 2017, have been updated to the 2026 version as part of the Japanese Circulation Society 2026 guidelines on the management of large vessel vasculitis, and are presented here in English for the first time. The revision was conducted through a 3-round modified Delphi process involving a panel of 21 experts, supplemented by email discussion and an in-person meeting. The updated criteria incorporate 3 major changes: new symptoms were added and a qualifying statement introduced in Section A; pulmonary artery involvement was elevated to a main criterion in Section B; and IgG4-related periaortitis, Cogan syndrome, and drug-induced aortitis were added in Section C. These updates reflect advances in imaging technology and international classification frameworks, with an emphasis on improving diagnostic sensitivity to reduce missed diagnoses.
SN - 1347-4820
SN - 1346-9843
ER -